Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) ...
The Central Bank said the firm failed to put effective arrangements in place to detect and report suspicious transactions.